How does a 340B TPA prevent diversion?
A 340B TPA helps prevent diversion by checking every claim against your eligibility rules before it counts as 340B. Each prescription has to trace back to a registered, eligible site, an eligible prescriber, a visit documented in your health record and a patient who was an outpatient at the time. Only claims that pass every check build up 340B replenishment, reversed claims are taken back out, and self-audits test samples to catch what the filters missed. The legal duty to prevent diversion stays with the covered entity; the TPA runs the controls you define and keeps the records that prove them.[1][3][5]
“A covered entity shall not resell or otherwise transfer the drug to a person who is not a patient of the entity.”
42 U.S.C. § 256b(a)(5)(B). Manufacturers and HRSA can audit the records that show compliance.[1]
How it shows up in HRSA audits
HRSA posts the findings from finalized covered entity audits. The diversion findings for fiscal year 2025 audits are mostly described in a few recurring phrases:[7]
- “340B drugs dispensed at contract pharmacies for prescriptions written at ineligible sites”
- “340B drugs dispensed at covered entity for prescriptions written at ineligible sites”
- “340B drug dispensed to inpatient”
Each of these is a claim that should have failed a check: the wrong site, or the wrong patient status. That is where a TPA’s controls do their work. For the audit process itself, see how to prepare for a HRSA 340B audit.
The patient test every claim has to pass
HRSA’s 1996 patient definition guidelines still guide its audits. Under them, an individual is a patient of a covered entity only if all of the following are true:[2][8]
- 1You have a relationship with the individual
The covered entity has established a relationship with the person and maintains records of their health care.
- 2Your professional is responsible for the care
The person receives care from a health care professional employed by the covered entity, or under a contract or other arrangement (such as a referral for consultation) where responsibility for the care stays with the covered entity.
- 3The service fits your grant or designation
For grantees and FQHC look-alikes, the service is consistent with the scope for which the grant or designation was given. Disproportionate share hospitals are exempt from this part.
Someone isn’t a patient if the only service they got from the covered entity was having a drug dispensed for use at home.[2]
A 2023 federal court decision in Genesis Health Care v. Becerra rejected a narrower HRSA reading of “patient,” but relief was limited to Genesis, and HRSA says the decision applies solely to Genesis Health Care.[8][9]
Seven checks a claim clears before it counts as 340B
HRSA’s contract pharmacy guidance calls for a tracking system suitable to prevent diversion and a system to verify patient eligibility. In practice, a TPA runs each dispense through a series of checks built from your data: sites, providers, encounters and patient status. A claim that fails any one of them stays non-340B.[3]
The originating clinic must be the parent site or a registered child site. For hospitals, the clinic has to appear as reimbursable on the most recently filed Medicare cost report, and off-site clinics must be registered in 340B OPAIS.[6][10]
Prescribers are matched to the providers you employ or contract with. Referral prescriptions qualify only when you keep a documented referral and the consult summary showing your responsibility for the care.[2][10][11]
The claim is matched to an encounter documented in the covered entity’s record, using the encounter rules your written policies set. A dispense with no supporting visit doesn’t qualify; dispensing alone doesn’t make someone your patient.[2][10][11]
340B is an outpatient program. Your policies define inpatient vs. outpatient (including observation and discharge prescriptions), and the TPA applies that definition to each use. Inpatient use is excluded.[4][6][10]
Only qualified dispenses accumulate, by exact 11-digit NDC, with billing units per package set correctly. Purchases, dispenses and inventory should reconcile, and any variance gets resolved and documented.[10]
Reversed claims and eligibility data corrections have to be removed from the balance. If 340B stock was already ordered against them, the result is an ineligible purchase to fix.[13]
Checks 6 and 7 are where inventory mechanics come in. For more detail, see what virtual inventory is in 340B and how accumulators and split billing work. Medicaid claims face a separate filter for duplicate discounts.
Three places diversion tends to slip in
Contract pharmacies
Contract pharmacies also fill prescriptions for the general public, which GAO noted increases the risk of 340B drugs going to ineligible patients. HRSA’s posted audit findings repeatedly cite contract pharmacy fills for prescriptions written at ineligible sites.[7][14]
Different eligibility logic
OIG found that covered entities, pharmacies and TPAs used different methods to identify eligible prescriptions, so similar prescriptions were treated differently from one entity to another. Your rules need to be written down and applied the same way everywhere.[15]
Mixed-use hospital areas
Where inpatients and outpatients are treated in the same department, HRSA says the hospital must have tracking systems that keep 340B drugs from being used for inpatients, and shouldn’t use 340B there if it can’t.[6]
Setting up pharmacies correctly is part of the fix. See how contract pharmacy setup works with a 340B TPA.
Self-audits that test whether the checks are working
Filters only catch what they’re configured for. HRSA recommends quarterly internal audits and annual independent audits of contract pharmacies, with written procedures for reviewing the eligibility system and reconciling dispensing, purchasing and billing records. The 2010 guidance gives examples: quarterly sample comparisons of eligible prescriptions to dispensing records, and a six-month comparison of 340B purchasing and dispensing records.[3][5]
Sample from purchases, then trace
- 1.Pick 20 invoices from 340B purchases: the 10 with the most lines and the 10 with the highest total cost
- 2.Choose 20 different drugs from those invoices, then one 340B dispense or administration of each
- 3.Check each one for eligible location, registered site, outpatient status, eligible provider and a documented visit
- 4.Reconcile units purchased, dispensed and on hand (or in the accumulator) for each drug
- 5.Pull one day of accumulations across the 340B, GPO and WAC accounts and confirm exact NDC matching
From the Prime Vendor Program’s quarterly self-audit for hospitals subject to the GPO prohibition.[10]
Sample from fills, then trace
- 1.Take a random sample from each pharmacy arrangement, larger for big chains (for example 30) than for a small independent (for example 10)
- 2.Add targeted picks: drugs likely to be miscalculated, high-cost specialty drugs and anything billed to Medicaid
- 3.Confirm each fill came from a registered pharmacy location under a signed agreement
- 4.Trace each prescription to an eligible service, an eligible prescriber and a documented encounter
- 5.For referral prescriptions, confirm your record shows responsibility for the care
From the Prime Vendor Program’s contract pharmacy self-audit, recommended at least quarterly.[11]
A good TPA makes this fast: every claim keeps the site, prescriber, encounter and accumulation history an auditor will trace. See what reporting a 340B TPA should provide.
When a claim shouldn’t have qualified
Fix the cause
Correct the rule, provider list, site mapping or unit setup that let the claim through, so the error stops recurring.[10]
Find the full extent
Look back for every claim the same error touched, not just the sampled ones. HRSA requires entities with audit findings to assess the full extent of noncompliance.[14]
Make manufacturers whole
Return or credit and rebill with the wholesaler while windows are open (typically 3–6 months from purchase for credit and rebill), otherwise repay the manufacturer directly. HRSA expects repayment even when an issue isn’t material.[13]
Decide on materiality
Compare the result to the material breach threshold in your policies. Adverse events include 340B drugs going to ineligible patients and 340B drugs missing from inventory.[12]
What stays your call
HRSA’s guidance says the covered entity has, and continues to bear, full responsibility for preventing diversion, even when a contract pharmacy and a TPA are involved. Your TPA applies your decisions to every claim, so the decisions need to be written down.[3]
For a full breakdown of duties, see who is responsible for 340B compliance.
- How your entity applies the patient definition, written in policies and procedures
- Where the line between inpatient and outpatient sits, including observation and discharge
- Which prescribers, referral arrangements and sites count, and keeping that list current
- Your material breach threshold and the decision to self-disclose
- Annual recertification, signed by your authorizing official
Eligibility checks you can stand behind
Precise eligibility matching
We configure eligibility matching to your sites, providers and policies, with referral capture beyond your walls, and run claim capture in real time across a 10,000+ pharmacy network.
Audit-ready claims
Every claim stays audit-ready, with duplicate discount monitoring, Good Faith Inquiry tracking and negative balance management, plus a dedicated account manager when you run a self-audit or face a HRSA audit.
Split billing that stays tied
Purchases are separated by patient eligibility across 340B, GPO and WAC accounts with no end-of-month true-ups. We support 300 covered entities, 24 of them hospitals.
Ready for 2027 rebates
The rebate module is Included for Aventi TPA clients, with real-time 340B ESP and Truzo (Kalderos) integration. Learn about the 2027 340B rebate model.
340B diversion prevention: common questions
Related pages
- Who is responsible for 340B compliance: TPA or covered entity
- How to prepare for a HRSA 340B audit
- What is virtual inventory in 340B?
- 340B accumulators and split billing
- How contract pharmacy setup works with a 340B TPA
- Duplicate discounts and the Medicaid Exclusion File
- What reporting a 340B TPA should provide
- What is a 340B TPA?
- The 2027 340B rebate model
- 340B TPA comparison
Sources
- 42 U.S.C. § 256b(a)(5)(B) (prohibiting resale or transfer), (a)(5)(C) (auditing) and (d)(2)(B)(v) (sanctions) (Cornell LII) — https://www.law.cornell.edu/uscode/text/42/256b
- Federal Register, Notice Regarding Section 602 of the Veterans Health Care Act of 1992, Patient and Entity Eligibility, 61 FR 55156 (Oct. 24, 1996), Definition of a Patient — https://www.govinfo.gov/content/pkg/FR-1996-10-24/html/96-27344.htm
- Federal Register, Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 FR 10272 (Mar. 5, 2010), essential elements (g) and (h) and appendix — https://www.federalregister.gov/documents/2010/03/05/2010-4755/notice-regarding-340b-drug-pricing-program-contract-pharmacy-services
- HRSA Office of Pharmacy Affairs, Program Integrity (audit procedures, repayment, repeat findings) — https://www.hrsa.gov/opa/program-integrity
- HRSA FAQ, What are the audit and compliance parameters under the contract pharmacy guidelines? — https://www.hrsa.gov/about/faqs/what-are-audit-compliance-parameters-under-contract-pharmacy-guidelines
- HRSA 340B FAQs (child site registration, four-walls clinics, discharge prescriptions, mixed-use settings, employees) — https://www.hrsa.gov/opa/faqs
- HRSA, Program Integrity: FY25 Audit Results (updated Oct. 30, 2026) — https://www.hrsa.gov/opa/program-integrity/fy-25-audit-results
- HRSA, 340B Patient Definition Compliance Resources — https://www.hrsa.gov/opa/educational-resources/patient-definition-resources
- Genesis Health Care, Inc. v. Becerra, No. 4:19-cv-01531-RBH (D.S.C. Nov. 3, 2023), order on summary judgment — https://storage.courtlistener.com/recap/gov.uscourts.scd.250571/gov.uscourts.scd.250571.143.0.pdf
- 340B Prime Vendor Program (Apexus), Self-Audit: Prevention of Diversion and GPO Violation (DSH/PED/CAN) — https://www.340bpvp.com/Documents/Public/340B%20Tools/gpo-prohibition-hospitals-self-audit-prevention-of-diversion-and-gpo-violation.docx
- 340B Prime Vendor Program (Apexus), Self-Audit: Contract Pharmacy — https://www.340bpvp.com/Documents/Public/340B%20Tools/self-audit-contract-pharmacy.docx
- 340B Prime Vendor Program (Apexus), Establishing Material Breach Threshold — https://www.340bpvp.com/Documents/Public/340B%20Tools/establishing-material-breach-threshold.docx
- Apexus, Expert Tip: Resolve Negative 340B Accumulations (340B Report, Nov. 30, 2023) — https://www.apexus.com/about-us/articles-and-updates/expert-tip-resolve-negative-340b-accumulations
- GAO-18-480, Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement (June 2018) — https://www.gao.gov/products/gao-18-480
- HHS Office of Inspector General, Contract Pharmacy Arrangements in the 340B Program, OEI-05-13-00431 (Feb. 2014) — https://oig.hhs.gov/reports/all/2014/contract-pharmacy-arrangements-in-the-340b-program/
Last updated November 20, 2026. This page is general information, not legal advice. Check HRSA’s current guidance and your own counsel for your program.